EU/3/20/2259: Orphan designation for the treatment of pancreatic cancer
2-hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate
Table of contents
Overview
On 24 March 2020, orphan designation EU/3/20/2259 was granted by the European Commission to MWB Consulting S.A.R.L., France, for 2-hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate (also known as GB1275) for the treatment of pancreatic cancer.
Key facts
Active substance |
2-hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate
|
Intended use |
Treatment of pancreatic cancer
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/20/2259
|
Date of designation |
24/03/2020
|
Sponsor |
MWB Consulting S.A.R.L. |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Update history
Date | Update |
---|---|
February 2023 | Please note that this product was withdrawn from the Union Register of orphan medicinal products on request of the Sponsor. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: